AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CYCLOPHARM LTD

0.825

-0.010-1.20%

Volume:50.86K

Turnover:42.60K

Market Cap:99.50M

PE:-6.79

High:0.860

Open:0.835

Low:0.825

Close:0.835

52wk High:1.550

52wk Low:0.560

Shares:120.61M

Float Shares:56.55M

Volume Ratio:0.82

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.121

EPS(LYR):-0.128

ROE:-31.98%

ROA:-15.65%

PB:2.76

PE(LYR):-6.43

Loading ...

Overview Company News Filings

BRIEF-Cyclopharm Posts FY Prelim Net Loss Attributable A$17.2 Million

Cyclopharm Ltd - FY Prelim Net Loss Attributable a$17.2 Mln

THOMSON REUTERS

Cyclopharm Ltd - Chairman David Heaney to Retire at 2026 AGM

THOMSON REUTERS

Cyclopharm Expands US Strategy With New Order, Contract; Shares Up 4%

MT Newswires Live

Cyclopharm Says Technegas Technology Approved for Use at National Institutes of Health in Maryland

MT Newswires Live

Cyclopharm Ltd-Technegas Approved at the US National Institutes of Health

THOMSON REUTERS

Cyclopharm Ltd-Share Purchase Plan Offer Booklet

THOMSON REUTERS

Cyclopharm Raises AU$14 Million via Placement; Shares Fall 17%

MT Newswires Live

BRIEF-Cyclopharm To Raise A$14 Million (Before Costs) At A$0.95 Per Share

BUZZ-Australia's Cyclopharm drops to one-week low on discounted placement

Cyclopharm Ltd - Spp to Raise up to a$2 Mln at a$0.95 per Share

THOMSON REUTERS

BRIEF-Cyclopharm Logs FY Unaudited Operating Revenue A$32.3 Mln

Cyclopharm Ltd - FY Unaudited Operating Revenue a$32.3 Mln

THOMSON REUTERS

BRIEF-Cyclopharm Seeks Trading Halt

Cyclopharm Enters Research Collaboration With Macquarie University To Evaluate Treatment For Chronic Obstructive Pulmonary Disease

MT Newswires Live

Cyclopharm's Lung Imaging Product Recognized as Preferred Agent in Draft Clinical Guideline; Shares Up 13%

MT Newswires Live

Cyclopharm Says Insurer Assumes Conduct of Defense Against 4DMedical Lawsuit In Victoria Supreme Court, Shares Jump 11%

MT Newswires Live

BRIEF-Cyclopharm Confirms Insurer Accepted Indemnity In Respect Of Proceedings

BUZZ-Australia's Cyclopharm rises on med-tech clinical guideline win in US

Cyclopharm Ltd - Confirms That Its Insurer Has Accepted Indemnity in Respect of Proceedings

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CYC.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CYC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CYC.AU\",,,,,undefined,":{"symbol":"CYC.AU","market":"AU","secType":"STK","nameCN":"CYCLOPHARM LTD","latestPrice":0.825,"timestamp":1772082720000,"preClose":0.835,"halted":0,"volume":50856,"delay":0,"changeRate":-0.011976047904191628,"nameEN":"CYCLOPHARM LTD","floatShares":56552486,"shares":120610534,"eps":-0.121448,"marketStatus":"Not Yet Opened","change":-0.01,"latestTime":"02-26 16:12:00 AEDT","open":0.835,"high":0.86,"low":0.825,"amount":42599,"amplitude":0.041916,"askPrice":0.875,"askSize":2500,"bidPrice":0.825,"bidSize":4894,"shortable":3,"etf":0,"ttmEps":-0.121448,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1772146800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.835,"openAndCloseTimeList":[[1772060400000,1772082000000]],"volumeRatio":0.8226384080240965,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CYC.AU\",,,,,undefined,":{"symbol":"CYC.AU","floatShares":56552486,"roa":"-15.65%","roe":"-31.98%","lyrEps":-0.128254,"volumeRatio":0.8226384080240965,"shares":120610534,"dividePrice":0,"high":0.86,"amplitude":0.041916,"preClose":0.835,"low":0.825,"week52Low":0.56,"pbRate":"2.76","psRate":"3.24","week52High":1.55,"institutionHeld":0,"latestPrice":0.825,"committee":0.323776,"eps":-0.121448,"divideRate":0,"volume":50856,"delay":0,"ttmEps":-0.121448,"open":0.835,"prevYearClose":0.98,"prevWeekClose":0.86,"prevMonthClose":1.17,"prevQuarterClose":0.98,"fiveDayClose":0.89,"twentyDayClose":1.23,"sixtyDayClose":0.79,"dividendGrowthYears":4,"dividendGrowthRate":0,"fiveYearAvgDividendRate":0.006534753846142799},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CYC.AU\",params:#limit:5,,,undefined,":[{"date":"2023-09-01","symbol":"CYC.AU","amount":0.005,"announcedDate":"2023-08-22","type":"dividend","market":"AU","newRecordDate":"2023-09-04","defaultRemindTime":1693526400000,"name":"Cyclopharm Ltd","recordDate":"2023-09-11","payableDate":"2023-09-04","currency":"AUD","dateTimestamp":1693490400000,"payDate":"2023-09-11"},{"market":"AU","date":"2023-03-27","symbol":"CYC.AU","amount":0.005,"defaultRemindTime":1679871600000,"name":"Cyclopharm Ltd","recordDate":"2023-04-04","payableDate":"2023-03-28","currency":"AUD","type":"dividend","dateTimestamp":1679835600000},{"market":"AU","date":"2022-09-02","symbol":"CYC.AU","amount":0.005,"defaultRemindTime":1662076800000,"name":"Cyclopharm Ltd","recordDate":"2022-09-12","payableDate":"2022-09-05","currency":"AUD","type":"dividend","dateTimestamp":1662040800000},{"market":"AU","date":"2022-04-04","symbol":"CYC.AU","amount":0.005,"defaultRemindTime":1649030400000,"name":"Cyclopharm Ltd","recordDate":"2022-04-12","payableDate":"2022-04-05","currency":"AUD","type":"dividend","dateTimestamp":1648994400000},{"market":"AU","date":"2021-09-03","symbol":"CYC.AU","amount":0.005,"defaultRemindTime":1630627200000,"name":"Cyclopharm Ltd","recordDate":"2021-09-13","payableDate":"2021-09-06","currency":"AUD","type":"dividend","dateTimestamp":1630591200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CYC.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-04","recordDate":"2020-09-07","paymentDate":"2020-09-14","value":0.005,"currency":"AUD"},{"executeDate":"2021-04-01","recordDate":"2021-04-06","paymentDate":"2021-04-13","value":0.005,"currency":"AUD"},{"executeDate":"2021-09-03","recordDate":"2021-09-06","paymentDate":"2021-09-13","value":0.005,"currency":"AUD"},{"executeDate":"2022-04-04","recordDate":"2022-04-05","paymentDate":"2022-04-12","value":0.005,"currency":"AUD"},{"executeDate":"2022-09-02","recordDate":"2022-09-05","paymentDate":"2022-09-12","value":0.005,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CYC.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614007387","title":"BRIEF-Cyclopharm Posts FY Prelim Net Loss Attributable A$17.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614007387","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614007387?lang=en_us&edition=fundamental","pubTime":"2026-02-25 18:20","pubTimestamp":1772014802,"startTime":"0","endTime":"0","summary":"BRIEF-Cyclopharm Posts FY Prelim Net Loss Attributable A$17.2 MillionFeb 25 (Reuters) - Cyclopharm Ltd CYC.AX:FY PRELIM OPERATING REVENUE A$32.3 MILLIONFY PRELIM NET LOSS ATTRIBUTABLE A$17.2 MILLIONFurther company coverage: CYC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZK1HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYC.AU","BK7007"],"gpt_icon":0},{"id":"2614777176","title":"Cyclopharm Ltd -  FY Prelim Net Loss Attributable a$17.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614777176","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614777176?lang=en_us&edition=fundamental","pubTime":"2026-02-25 14:13","pubTimestamp":1771999993,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZK1HV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","CYC.AU"],"gpt_icon":0},{"id":"2614776237","title":"Cyclopharm Ltd - Chairman David Heaney to Retire at 2026 AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2614776237","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614776237?lang=en_us&edition=fundamental","pubTime":"2026-02-25 14:06","pubTimestamp":1771999599,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL0JJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CYC.AU","BK7007"],"gpt_icon":0},{"id":"2612479956","title":"Cyclopharm Expands US Strategy With New Order, Contract; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612479956","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612479956?lang=en_us&edition=fundamental","pubTime":"2026-02-19 11:59","pubTimestamp":1771473593,"startTime":"0","endTime":"0","summary":"Cyclopharm (ASX:CYC) secured a purchase order from the National Institutes of Health and a contract with Texas Health Presbyterian Hospital Dallas, part of Texas Health Resources, according to a Thurs","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7007","CYC.AU"],"gpt_icon":0},{"id":"2612492944","title":"Cyclopharm Says Technegas Technology Approved for Use at National Institutes of Health in Maryland","url":"https://stock-news.laohu8.com/highlight/detail?id=2612492944","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612492944?lang=en_us&edition=fundamental","pubTime":"2026-02-18 10:08","pubTimestamp":1771380517,"startTime":"0","endTime":"0","summary":"Cyclopharm  said that its Technegas technology, which provides high-resolution ventilation imaging at the site where oxygen is taken up in the lung, was approved for clinical use at the National Institutes of Health  in Bethesda, Maryland, according to a Wednesday Australian bourse filing.The firm received a formal purchase order, and installation is expected in the coming weeks. The technology will be used for clinical ventilation imaging within NIH's protocol-driven clinical program.The contract leverages the firm's five-year federal supply schedule agreement, which provides streamlined procurement access across US federal healthcare institutions.Its shares rose 1% in recent trading on Wednesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7007","NHLD","CYC.AU"],"gpt_icon":0},{"id":"2612222494","title":"Cyclopharm Ltd-Technegas Approved at the US National Institutes of Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2612222494","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612222494?lang=en_us&edition=fundamental","pubTime":"2026-02-18 09:32","pubTimestamp":1771378367,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nTUEBD0GSZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","CYC.AU"],"gpt_icon":0},{"id":"2610964464","title":"Cyclopharm Ltd-Share Purchase Plan Offer Booklet","url":"https://stock-news.laohu8.com/highlight/detail?id=2610964464","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610964464?lang=en_us&edition=fundamental","pubTime":"2026-02-12 06:10","pubTimestamp":1770847832,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUE15SHPC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CYC.AU","BK7007"],"gpt_icon":0},{"id":"2608433329","title":"Cyclopharm Raises AU$14 Million via Placement; Shares Fall 17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608433329","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608433329?lang=en_us&edition=fundamental","pubTime":"2026-02-04 10:50","pubTimestamp":1770173416,"startTime":"0","endTime":"0","summary":"Cyclopharm  raised AU$14 million via a two-tranche placement of 14.7 million new shares at AU$0.95 per share to new and existing institutional, sophisticated, and professional investors, according to a Wednesday filing with the Australian bourse.The company will issue 9.5 million shares on Feb.11, followed by 5.3 million shares on Feb.25, the filing said.Additionally, the company plans to undertake a share purchase plan at the same price to raise a further AU$2 million, the filing added.Funds raised will be used to advance the commercial rollout of Technegas in the US, the company said.The new shares under the second tranche of the placement are expected to settle on Feb. 24.Shares of the company fell 17% in recent Wednesday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7007","CYC.AU"],"gpt_icon":0},{"id":"2608387901","title":"BRIEF-Cyclopharm To Raise A$14 Million (Before Costs) At A$0.95 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2608387901","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608387901?lang=en_us&edition=fundamental","pubTime":"2026-02-04 09:18","pubTimestamp":1770167931,"startTime":"0","endTime":"0","summary":"BRIEF-Cyclopharm To Raise A$14 Million (Before Costs) At A$0.95 Per ShareFeb 4 (Reuters) - Cyclopharm CYC.AX:PLACEMENT TO RAISE A$14 MILLION (BEFORE COSTS) AT A$0.95 PER SHARESPP TO RAISE UP TO A$2 MILLION AT A$0.95 PER SHAREFurther company coverage: CYC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nFWN3YZ14P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYC.AU","BK7007"],"gpt_icon":0},{"id":"2608873823","title":"BUZZ-Australia's Cyclopharm drops to one-week low on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2608873823","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608873823?lang=en_us&edition=fundamental","pubTime":"2026-02-04 09:09","pubTimestamp":1770167341,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Cyclopharm drops to one-week low on discounted placement** Shares of Cyclopharm CYC.AX fall as much as 19.7% to A$0.94, their lowest level since January 27** The radiopharmaceutical c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nL4N3Z003D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","CYC.AU"],"gpt_icon":0},{"id":"2608261386","title":"Cyclopharm Ltd - Spp to Raise up to a$2 Mln at a$0.95 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2608261386","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608261386?lang=en_us&edition=fundamental","pubTime":"2026-02-04 06:40","pubTimestamp":1770158437,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YZ14P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CYC.AU","BK7007"],"gpt_icon":0},{"id":"2608588073","title":"BRIEF-Cyclopharm Logs FY Unaudited Operating Revenue A$32.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2608588073","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608588073?lang=en_us&edition=fundamental","pubTime":"2026-02-02 09:04","pubTimestamp":1769994293,"startTime":"0","endTime":"0","summary":"BRIEF-Cyclopharm Logs FY Unaudited Operating Revenue A$32.3 MlnFeb 2 (Reuters) - Cyclopharm Ltd CYC.AX:FY UNAUDITED OPERATING REVENUE A$32.3 MILLIONFurther company coverage: CYC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nFWN3YX05T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","CYC.AU"],"gpt_icon":0},{"id":"2608002884","title":"Cyclopharm Ltd - FY Unaudited Operating Revenue a$32.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2608002884","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608002884?lang=en_us&edition=fundamental","pubTime":"2026-02-02 06:40","pubTimestamp":1769985632,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260201:nFWN3YX05T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CYC.AU","BK7007"],"gpt_icon":0},{"id":"2608884498","title":"BRIEF-Cyclopharm Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2608884498","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608884498?lang=en_us&edition=fundamental","pubTime":"2026-02-02 06:13","pubTimestamp":1769984020,"startTime":"0","endTime":"0","summary":"BRIEF-Cyclopharm Seeks Trading HaltFeb 2 (Reuters) - Cyclopharm Ltd CYC.AX:REQUESTS TRADING HALT FOR CAPITAL RAISINGFurther company coverage: CYC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260201:nFWN3YX05N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","CYC.AU"],"gpt_icon":0},{"id":"2607656772","title":"Cyclopharm Enters Research Collaboration With Macquarie University To Evaluate Treatment For Chronic Obstructive Pulmonary Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2607656772","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607656772?lang=en_us&edition=fundamental","pubTime":"2026-01-29 13:29","pubTimestamp":1769664563,"startTime":"0","endTime":"0","summary":"Cyclopharm  entered a clinical research collaboration with Macquarie University and Macquarie University Hospital to evaluate a new treatment approach for patients with severe chronic obstructive pulmonary disease, the Endoscopic Segmental Sealant Ablation  study, according to a Thursday Australian bourse filing.The ESSA procedure is a minimally invasive bronchoscopic treatment targeting damaged parts of the lung at a smaller, segment-by-segment level, seeking to induce segmental lung volume reduction with the instillation of polymer foam.The study will use artificial intelligence-based lung imaging technology from Thirona, applied to nuclear medicine ventilation-perfusion (V/Q) single-photon emission computed tomography-computed tomography scans generated using Technegas.The study will recruit 34 patients with severe or very severe chronic obstructive pulmonary disease.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7046","BK4211","BK4195","ESSA","BK7007","MQG.AU","BK7511","CYC.AU"],"gpt_icon":0},{"id":"2606276575","title":"Cyclopharm's Lung Imaging Product Recognized as Preferred Agent in Draft Clinical Guideline; Shares Up 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606276575","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606276575?lang=en_us&edition=fundamental","pubTime":"2026-01-27 10:25","pubTimestamp":1769480725,"startTime":"0","endTime":"0","summary":"Cyclopharm  said its Technegas lung imaging product was recognized as a preferred ventilation agent in a new draft clinical guideline for lung imaging, according to a Tuesday filing with the Australian bourse.The Procedure Standard and Guideline for Ventilation-Perfusion Pulmonary Scintigraphy recognized Technegas for clinical use in the US, designating it as a preferred ventilation agent when available, the filing said.The draft guideline has been released for public consultation and will be refined for factual variations, per the filing.Shares rose 13% in afternoon trade on Tuesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7007","CYC.AU"],"gpt_icon":0},{"id":"2606275051","title":"Cyclopharm Says Insurer Assumes Conduct of Defense Against 4DMedical Lawsuit In Victoria Supreme Court, Shares Jump 11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606275051","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606275051?lang=en_us&edition=fundamental","pubTime":"2026-01-27 10:15","pubTimestamp":1769480153,"startTime":"0","endTime":"0","summary":"Cyclopharm  confirmed that its insurer accepted indemnity regarding proceedings brought by 4DMedical  in the Supreme Court of Victoria against the firm and the insurer assumed conduct of the defense on Cyclopharm's behalf, according to a Tuesday Australian bourse filing.4DMedical sued the firm over allegedly misleading comments made during a March webinar, claiming the comment about its capital raising statements was false and misleading, and alleging that it caused damage to the company.Its shares jumped 11% in recent trading on Tuesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4095","BK7094","CYC.AU","4DX.AU","VCCTF","BK7007"],"gpt_icon":1},{"id":"2606782422","title":"BRIEF-Cyclopharm Confirms Insurer Accepted Indemnity In Respect Of Proceedings","url":"https://stock-news.laohu8.com/highlight/detail?id=2606782422","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606782422?lang=en_us&edition=fundamental","pubTime":"2026-01-27 09:18","pubTimestamp":1769476693,"startTime":"0","endTime":"0","summary":"BRIEF-Cyclopharm Confirms Insurer Accepted Indemnity In Respect Of ProceedingsJan 27  - Cyclopharm Ltd CYC.AX:CONFIRMS THAT ITS INSURER HAS ACCEPTED INDEMNITY IN RESPECT OF PROCEEDINGSREFERS TO LODGEMENT OF LEGAL PROCEEDINGS BY 4DMEDICAL AGAINST CYCLOPHARMFurther company coverage: CYC.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nFWN3YR0QE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYC.AU","BK7007"],"gpt_icon":0},{"id":"2606426278","title":"BUZZ-Australia's Cyclopharm rises on med-tech clinical guideline win in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2606426278","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606426278?lang=en_us&edition=fundamental","pubTime":"2026-01-27 09:14","pubTimestamp":1769476465,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Cyclopharm rises on med-tech clinical guideline win in US** Shares of Cyclopharm CYC.AX advance as much as 15.34% to A$1.015, their biggest intraday pct gain December 1, 2025** The ra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nL6N3YS02L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7094","4DX.AU","CYC.AU","BK7007"],"gpt_icon":0},{"id":"2606226770","title":"Cyclopharm Ltd - Confirms That Its Insurer Has Accepted Indemnity in Respect of Proceedings","url":"https://stock-news.laohu8.com/highlight/detail?id=2606226770","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606226770?lang=en_us&edition=fundamental","pubTime":"2026-01-27 05:27","pubTimestamp":1769462878,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nFWN3YR0QE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","CYC.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":33,"code":"91000000","status":"200"}]}}